Clinical Trial Update: Anti-MAG First Administration to Human [Phase 1]

View source ↗

Summary

First-in-human Phase 1 administration of an anti-MAG agent completed in a study sponsored by GlaxoSmithKline for cerebrovascular accident (stroke).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Anti-MAG (anti-MAG antibody)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cerebrovascular Accident | Phase 1 | Status: COMPLETED